Dundee, UK, 7 July, 2015 – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF™) technology to replicate natural blood flow for enhanced patient outcomes, today announces the issue of three new patents, expected to strengthen the Company’s offering in both Asian and global markets.
Vascular Flow Technologies’ has expanded its patent landscape with patents for a tubular conduit issued by the Japanese patent office, 2012-538404, a flexible bypass graft issued by the Chinese patent office, 201080052130.X, and a drug delivery stent issued by the European patent office, 05702119.8.
All three devices use Vascular Flow Technologies’ SLF™ technology, a helical design clinically proven to replicate the natural spiral laminar flow pattern of blood. By promoting natural blood flow, SLF™ eliminates risk of turbulent flow and dead regions, which can lead to complications for the patient such as plaque formation, reduced blood flow and thrombosis.
The new patents will add to the existing suite of patents protecting SLF™ technology and Vascular Flow Technologies’ portfolio of vascular products, supporting the Company’s strategic growth plan.
Bill Allan, CEO of Vascular Flow Technologies, commented: “Japan is the second largest market globally for medical technology, and with an aging population, this is an important area for our investment.
The addition of these patents in Japan and China follow recent successes in both the EU and the US, strong clinical evidence in Europe and the USA and expansion of distribution networks, the launch of the STAAR Registry collaboration with Society of Vascular Surgery (USA) and the appointment of key internal personnel.”
About Vascular Flow Technologies
Vascular Flow Technologies is a leading innovator focused on the research, development and commercialisation of devices to improve blood flow in compromised or diseased blood vessels utilising its proprietary Spiral Laminar FlowTM (SLF™) technology. Natural blood flow has a distinctive singular spiral flow pattern and the patented SLF™ technology is the only clinically-proven design to replicate this.
VFT has two CE marked and FDA approved devices commercialised in Europe and the US, the Spiral Flow™ peripheral bypass (PV) graft and the Spiral Flow™ arteriovenous access (AV) graft. The SLF™ technology is used to create a longer lasting graft or stent, producing a better quality of life for the patient due to reduced vascular complications and improved longevity of the implant.
VFT is a privately held company with headquarters in Dundee, UK.
Further information is available at www.vascular-flow.com.
Issued for and on behalf of Vascular Flow Technologies by Instinctif Partners.
For more information, please contact VFT@instinctif.com